

CAMD Access Statistics (through 6/7/16)

Following CAMD's [May 2, 2016, announcement](#) that it will integrate with the Global Alzheimer's Association Interactive Network (GAAIN), the access to CAMD's Alzheimer's Disease Data Collaboration Center has continued to grow, as has the use of the Clinical Trial Simulation Tool. Below are the metrics through June 7, 2016.

Access statistics – CAMD Clinical Trial Simulation Tool (as of June 7, 2016)



CAMD'S CLINICAL TRIAL SIMULATION TOOL FOR ALZHEIMER'S DISEASE

54

Organizations

AstraZeneca
Biogen
Bristol-Myers Squibb
Lilly
Merck
Pfizer
Takeda

...and others

67

Individuals



16

Academic
Institutions



...and others

Access statistics – CAMD Alzheimer’s disease database (as of June 7, 2016)



CAMD’S ALZHEIMER’S DISEASE DATABASE

236
Organizations

- Abbott
- ALSTDI
- ALZFORUM
- BILL & MELINDA GATES foundation
- GE Global Research
- Genentech
- GlaxoSmithKline
- National Institutes of Health
- The Michael J. Fox Foundation
- ...and others

333
Individuals



86
Academic Institutions

- AMHERST COLLEGE
- EMORY UNIVERSITY
- HARVARD MEDICAL SCHOOL
- JOHNS HOPKINS UNIVERSITY
- UNIVERSITY OF ABERDEEN
- UNIVERSITY OF CAPE TOWN
- Duke University School of Medicine
- GOETHE UNIVERSITÄT FRANKFURT AM MAIN
- GEORGETOWN UNIVERSITY Georgetown University Medical Center
- SEOUL NATIONAL UNIVERSITY
- THE UNIVERSITY OF AUCKLAND
- UNIVERSITÄTS KLINIKUM KÖLN
- ...and others